Results 301 to 310 of about 244,635 (318)

Diffuse Large B-Cell Lymphomas

2010
De novo diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma worldwide, accounting for approximately 30–40% of adult non-Hodgkin lymphomas. It is defined as a diffuse proliferation of large neoplastic B lymphoid cells with a nuclear size equal to or exceeding that of a normal macrophage or more than twice the size of a normal lymphocyte ...
openaire   +2 more sources

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Nature, 2000
Ash A. Alizadeh, M. Eisen, R. Davis, Chishieva Ma, I. Lossos, A. Rosenwald, Jennifer C. Boldrick, H. Sabet, T. Tran, Xin Yu, J. Powell, Liming Yang, G. Marti, T. Moore, J. Hudson, Li-Sheng Lu, D. Lewis, R. Tibshirani, G. Sherlock, W. C. Chan, T. Greiner, D. Weisenburger, J. Armitage, R. Warnke, R. Levy, W. Wilson, M. Grever, J. Byrd, D. Botstein, Pat Brown, L. Staudt   +30 more
semanticscholar   +1 more source

Endobronchial Diffuse Large B-cell Lymphoma

Archivos de Bronconeumología (English Edition), 2020
Masahiro, Yamasaki, Yu, Matsumoto, Noboru, Hattori   +2 more
openaire   +2 more sources

Diffuse large B-cell lymphoma

2001
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 35–40% of all cases of NHL. Despite high reported response rates to anthracycline-based combination chemotherapy regimens, only 50–65% of patients with this disease have achieved long-term disease-free survival with this approach.
John W. Sweetenham, Andrew Wotherspoon, Andreas Rosenwald, German Ott   +3 more
openaire   +1 more source

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Nature Medicine, 2002
M. Shipp, Ken N. Ross, P. Tamayo, Andrew P. Weng, Jeffery L. Kutok, Ricardo C. T. Aguiar, M. Gaasenbeek, Michael Angelo, Michael Reich, Geraldine S. Pinkus, Tane S. Ray, Margaret A. Koval, K. Last, Andrew Norton, T. A. Lister, J. Mesirov, Donna S Neuberg, Eric S. Lander, Jon C. Aster, Todd R. Golub   +19 more
semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Yescarta, axicabtagene ciloleucel, Lymphoma, Follicular,Lymphoma, Large B-Cell, Diffuse, Date of authorisation: 23/08/2018, Revision: 2, Status: Authorised

Case Medical Research, 2019

semanticscholar   +1 more source

Treatment strategies for patients with diffuse large B-cell lymphoma.

Cancer Treatment Reviews, 2022
S. Poletto, M. Novo, L. Paruzzo, P. Frascione, U. Vitolo   +4 more
semanticscholar   +1 more source

Treatment resistance in diffuse large B-cell lymphoma

Leukemia, 2021
Michael Y. He, R. Kridel
semanticscholar   +1 more source

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

The Lancet Oncology, 2006
M. Pfreundschuh, L. Trümper, A. Osterborg, R. Pettengell, M. Trněný, K. Imrie, D. Ma, D. Gill, J. Walewski, P. Zinzani, R. Stahel, S. Kvaløy, O. Shpilberg, U. Jaeger, M. Hansen, T. Lehtinen, A. López-Guillermo, C. Corrado, A. Scheliga, N. Milpied, M. Mendila, M. Rashford, E. Kuhnt, M. Loeffler   +23 more
semanticscholar   +1 more source

Diffuse Large B-Cell Lymphoma Subtypes

2013
Faramarz Naeim, P. Nagesh Rao, Sophie X. Song, Ryan T. Phan   +3 more
openaire   +1 more source